KRYS | Ticker Profile - Titan Protect

KRYS

Krystal Biotech, Inc.

Healthcare · Biotechnology · NMS

$301.00

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$9.0B

Total market value of the company

Trailing P/E

40.99

Expensive — high growth expected

Forward P/E

30.42

Based on estimated future earnings — lower means cheaper

Rev Growth

+31.9%

Year-over-year revenue change

Profit Margin

53.9%

How much profit the company keeps from each dollar of revenue

ROE

19.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$310.00

+3% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

https://www.krystalbio.com

Country: United States Employees: 295 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.041

Excellent risk-adjusted returns

Kelly Fraction

0.0872

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.974

Acceptable balance between returns and drawdown risk

Annual Return

41.2%

Historical annualised return based on price data

Max Drawdown

-42.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

205

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.50

Very low correlation to market moves

52W High

$319.48

6% below the year high

52W Low

$123.03

145% above the year low

Avg Volume

280,475

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

17.7%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$7.48

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.71

Moderate leverage — manageable

Current Ratio

9.46

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

8.82

Like current ratio but excludes inventory — stricter test

Gross Margin

94.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

46.1%

Profit from core operations before interest and tax

Free Cash Flow

$137M

Positive — the business generates more cash than it spends

Revenue (TTM)

$417M

Total revenue over the last 12 months

Net Income

$225M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$399.00

Target Median

$310.00

Target Low

$241.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go